Figure 5.
Survival curves of NKTCL patients included in this study. PFS (A) and OS (B) of the entire cohort. (C) Comparison of PFS between patients with a clearance of ctDNA and those with persisting detectable ctDNA during monitoring. (D) Comparison of PFS between patients with high and low baseline plasma cfDNA concentration.